The role of quizartinib in the treatment of acute myeloid leukemia.

Publication Type:

Journal Article


Expert opinion on investigational drugs, Volume 22, Issue 12, p.1659-69 (2013)


2013, Clinical Research Division, January 2014


Approximately one-third of the patients with acute myeloid leukemia (AML) harbor internal tandem duplication (ITD) in the gene encoding FMS-like tyrosine kinase 3 (FLT3-ITD), which is associated with poor prognosis. Over the course of the last decade, several FLT3 inhibitors have been developed. Nevertheless, the pharmacokinetic limitations of some of these compounds as well as their potency have limited their therapeutic efficacy. Quizartinib (AC220) is a second-generation FLT3 inhibitor that has shown promising activity in AML in Phase II clinical trials.